Drug Developer Must Face Suboxone Product-Hopping Claims
A Pennsylvania federal judge found that sufficient evidence supports allegations that drug delivery developer MonoSol Rx LLC engaged in an anti-competitive scheme to delay generic versions of an opioid addiction treatment,...To view the full article, register now.
Already a subscriber? Click here to view full article